Global Anticancer Drugs research

Anticancer Drugs Comprehensive Study by Application (Hospitals & Clinics, Oncological Research Centres), Drug Type (Targeted Drugs, Cytotoxic Drugs), Distribution Chanel (Direct, Indirect), Treatment Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Others), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Prostate Cancer, Others) Players and Region - Global Market Outlook to 2028

Anticancer Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Anticancer Drugs Market Scope
Anticancer drug also known as antineoplastic drug. Any drug which is effective in the treatment of malignant, or tumorous diseases is known as anticancer drugs. The major classes of anticancer drugs comprises of alkylating agents, natural products, antimetabolites, and hormones. This drugs contains alkylating agents like ifosfamide, cyclophosphamide, melphalan, and others. This drugs are used to kill proliferating cancer cells. Spread of cancer is mainly occur by the rapid outburst of abnormal cells apart from their boundaries. This abnormal cells invades adjoining organs. Changing lifestyle, rising number of geriatric population leads to rise in prevalence of cancer across the globe. According to study, 2.3 million cases of cancer was estimated in 2020. Majorly lung, breast and colorectal cancer contributed to the new incidence cases. Thus, with rising incidence cases, the demand for anticancer drugs has been raised. Governments & research organisations across the globe are focusing to spread awareness regarding cancer treatments majorly in African countries. Thus, pharmaceutical companies are focusing on providing new products lines for the treatment of advanced cancers which is anticipated to drive the market growth over forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledNovartis AG (Switzerland), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India) and LOGENEX Pharm GmbH (Germany)
CAGR%


Anticancer Drugs market is a fragmented market due to the presence of various players. The players are focusing on developing new combinations drugs to improve quality, enhances and promotes performance. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Novartis AG (Switzerland), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India) and LOGENEX Pharm GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Shilpa Therapeutics Pvt. Ltd (India), Amgen (United States) and AQVIDA GmbH (Germany).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Anticancer Drugs market by Type , by Application (Hospitals & Clinics and Oncological Research Centres) and Region with country level break-up.

On the basis of geography, the market of Anticancer Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In December 2019, Merck & Co. has acquired ArQule Inc. ArQule Inc is mainly developing kinases inhibitors. This acquisition was valued at USD 2.7 billion. Through this acquisition, company is able to expands its anticancer drugs portfolio., and In December 2019, Sanofi completed acquisition of Synthorx Inc. Synthorx Inc is manufacturers of immunotherapies. This acquisition was valued at USD2.5 billion. With this acquisition, company has strengthen its immunotherapy offerings.
In April 2020, Shilpa Medicare Ltd. has launched generic version of cancer drug Dasatinib. Dasashil revolutionise version which offers the treatment by ensuring availability of therapy to Indian patients. With this new launch, company is able to provide generic version which have huge affordability for patients.
BLA- A biologics license application (BLA) is defined by the U.S. Food and Drug Administration (FDA). It is regulated under 21 CFR 600 – 680. The biologics license application is a permission to introduce, a biologic product into interstate commerce (21 CFR 601.2).

Influencing Trend:
Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Cancers

Market Growth Drivers:
Growing Expenditure of Pharmaceutical Industry, Increasing Cancer Incidence across the Globe and Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments

Challenges:
Huge Requirement of Investments for Drug Developments

Restraints:
Huge Treatment Cost of Advanced Cancer May Restrain Its Demand and Side Effects Associated With Anti-Cancer Drugs Expected To Hamper Its Demand

Opportunities:
Government Funding’s For Oncological Research Centers to Develop Novel Drugs and Rising Approvals for Anticancer Drugs to Advanced Cancer Has Created Growth Opportunities for Market

Key Target Audience
Anti-Cancer Drugs Manufacturers/Suppliers/Distributor, Raw Material Suppliers, Oncological Research Centers, New Entrants/Investors, Strategic Business Planners, Governments and End Use Industry

Report Objectives / Segmentation Covered

By Application
  • Hospitals & Clinics
  • Oncological Research Centres
By Drug Type
  • Targeted Drugs
  • Cytotoxic Drugs

By Distribution Chanel
  • Direct
  • Indirect

By Treatment Therapy
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Others

By Cancer Type
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Expenditure of Pharmaceutical Industry
      • 3.2.2. Increasing Cancer Incidence across the Globe
      • 3.2.3. Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments
    • 3.3. Market Challenges
      • 3.3.1. Huge Requirement of Investments for Drug Developments
    • 3.4. Market Trends
      • 3.4.1. Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Cancers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anticancer Drugs, by Application, Drug Type, Distribution Chanel, Treatment Therapy, Cancer Type and Region (value and volume ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anticancer Drugs (Value)
      • 5.2.1. Global Anticancer Drugs by: Application (Value)
        • 5.2.1.1. Hospitals & Clinics
        • 5.2.1.2. Oncological Research Centres
      • 5.2.2. Global Anticancer Drugs by: Drug Type (Value)
        • 5.2.2.1. Targeted Drugs
        • 5.2.2.2. Cytotoxic Drugs
      • 5.2.3. Global Anticancer Drugs by: Distribution Chanel (Value)
        • 5.2.3.1. Direct
        • 5.2.3.2. Indirect
      • 5.2.4. Global Anticancer Drugs by: Treatment Therapy (Value)
        • 5.2.4.1. Chemotherapy
        • 5.2.4.2. Radiation Therapy
        • 5.2.4.3. Immunotherapy
        • 5.2.4.4. Others
      • 5.2.5. Global Anticancer Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anticancer Drugs (Volume)
      • 5.3.1. Global Anticancer Drugs by: Application (Volume)
        • 5.3.1.1. Hospitals & Clinics
        • 5.3.1.2. Oncological Research Centres
      • 5.3.2. Global Anticancer Drugs by: Drug Type (Volume)
        • 5.3.2.1. Targeted Drugs
        • 5.3.2.2. Cytotoxic Drugs
      • 5.3.3. Global Anticancer Drugs by: Distribution Chanel (Volume)
        • 5.3.3.1. Direct
        • 5.3.3.2. Indirect
      • 5.3.4. Global Anticancer Drugs by: Treatment Therapy (Volume)
        • 5.3.4.1. Chemotherapy
        • 5.3.4.2. Radiation Therapy
        • 5.3.4.3. Immunotherapy
        • 5.3.4.4. Others
      • 5.3.5. Global Anticancer Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
  • 6. Anticancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hoffmann-La Roche Ltd. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astra Zeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celgene (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly & Co (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cadila Healthcare Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. LOGENEX Pharm GmbH (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Anticancer Drugs Sale, by Application, Drug Type, Distribution Chanel, Treatment Therapy, Cancer Type and Region (value and volume ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anticancer Drugs (Value)
      • 7.2.1. Global Anticancer Drugs by: Application (Value)
        • 7.2.1.1. Hospitals & Clinics
        • 7.2.1.2. Oncological Research Centres
      • 7.2.2. Global Anticancer Drugs by: Drug Type (Value)
        • 7.2.2.1. Targeted Drugs
        • 7.2.2.2. Cytotoxic Drugs
      • 7.2.3. Global Anticancer Drugs by: Distribution Chanel (Value)
        • 7.2.3.1. Direct
        • 7.2.3.2. Indirect
      • 7.2.4. Global Anticancer Drugs by: Treatment Therapy (Value)
        • 7.2.4.1. Chemotherapy
        • 7.2.4.2. Radiation Therapy
        • 7.2.4.3. Immunotherapy
        • 7.2.4.4. Others
      • 7.2.5. Global Anticancer Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anticancer Drugs (Volume)
      • 7.3.1. Global Anticancer Drugs by: Application (Volume)
        • 7.3.1.1. Hospitals & Clinics
        • 7.3.1.2. Oncological Research Centres
      • 7.3.2. Global Anticancer Drugs by: Drug Type (Volume)
        • 7.3.2.1. Targeted Drugs
        • 7.3.2.2. Cytotoxic Drugs
      • 7.3.3. Global Anticancer Drugs by: Distribution Chanel (Volume)
        • 7.3.3.1. Direct
        • 7.3.3.2. Indirect
      • 7.3.4. Global Anticancer Drugs by: Treatment Therapy (Volume)
        • 7.3.4.1. Chemotherapy
        • 7.3.4.2. Radiation Therapy
        • 7.3.4.3. Immunotherapy
        • 7.3.4.4. Others
      • 7.3.5. Global Anticancer Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anticancer Drugs: by Application(USD Million)
  • Table 2. Anticancer Drugs Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 3. Anticancer Drugs Oncological Research Centres , by Region USD Million (2017-2022)
  • Table 4. Anticancer Drugs: by Drug Type(USD Million)
  • Table 5. Anticancer Drugs Targeted Drugs , by Region USD Million (2017-2022)
  • Table 6. Anticancer Drugs Cytotoxic Drugs , by Region USD Million (2017-2022)
  • Table 7. Anticancer Drugs: by Distribution Chanel(USD Million)
  • Table 8. Anticancer Drugs Direct , by Region USD Million (2017-2022)
  • Table 9. Anticancer Drugs Indirect , by Region USD Million (2017-2022)
  • Table 10. Anticancer Drugs: by Treatment Therapy(USD Million)
  • Table 11. Anticancer Drugs Chemotherapy , by Region USD Million (2017-2022)
  • Table 12. Anticancer Drugs Radiation Therapy , by Region USD Million (2017-2022)
  • Table 13. Anticancer Drugs Immunotherapy , by Region USD Million (2017-2022)
  • Table 14. Anticancer Drugs Others , by Region USD Million (2017-2022)
  • Table 15. South America Anticancer Drugs, by Country USD Million (2017-2022)
  • Table 16. South America Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 17. South America Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 18. South America Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 19. South America Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 20. South America Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 21. Brazil Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 22. Brazil Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 23. Brazil Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 24. Brazil Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 25. Brazil Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 26. Argentina Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 27. Argentina Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 28. Argentina Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 29. Argentina Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 30. Argentina Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 31. Rest of South America Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 32. Rest of South America Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 33. Rest of South America Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 34. Rest of South America Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 35. Rest of South America Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 36. Asia Pacific Anticancer Drugs, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 38. Asia Pacific Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 39. Asia Pacific Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 40. Asia Pacific Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 41. Asia Pacific Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 42. China Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 43. China Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 44. China Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 45. China Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 46. China Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 47. Japan Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 48. Japan Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 49. Japan Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 50. Japan Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 51. Japan Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 52. India Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 53. India Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 54. India Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 55. India Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 56. India Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 57. South Korea Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 58. South Korea Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 59. South Korea Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 60. South Korea Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 61. South Korea Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 62. Taiwan Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 63. Taiwan Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 64. Taiwan Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 65. Taiwan Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 66. Taiwan Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 67. Australia Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 68. Australia Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 69. Australia Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 70. Australia Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 71. Australia Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 72. Rest of Asia-Pacific Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 73. Rest of Asia-Pacific Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 74. Rest of Asia-Pacific Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 75. Rest of Asia-Pacific Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 76. Rest of Asia-Pacific Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 77. Europe Anticancer Drugs, by Country USD Million (2017-2022)
  • Table 78. Europe Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 79. Europe Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 80. Europe Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 81. Europe Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 82. Europe Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 83. Germany Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 84. Germany Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 85. Germany Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 86. Germany Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 87. Germany Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 88. France Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 89. France Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 90. France Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 91. France Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 92. France Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 93. Italy Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 94. Italy Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 95. Italy Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 96. Italy Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 97. Italy Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 98. United Kingdom Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 99. United Kingdom Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 100. United Kingdom Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 101. United Kingdom Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 102. United Kingdom Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 103. Netherlands Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 104. Netherlands Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 105. Netherlands Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 106. Netherlands Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 107. Netherlands Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 108. Rest of Europe Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 109. Rest of Europe Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 110. Rest of Europe Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 111. Rest of Europe Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 112. Rest of Europe Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 113. MEA Anticancer Drugs, by Country USD Million (2017-2022)
  • Table 114. MEA Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 115. MEA Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 116. MEA Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 117. MEA Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 118. MEA Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 119. Middle East Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 120. Middle East Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 121. Middle East Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 122. Middle East Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 123. Middle East Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 124. Africa Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 125. Africa Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 126. Africa Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 127. Africa Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 128. Africa Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 129. North America Anticancer Drugs, by Country USD Million (2017-2022)
  • Table 130. North America Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 131. North America Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 132. North America Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 133. North America Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 134. North America Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 135. United States Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 136. United States Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 137. United States Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 138. United States Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 139. United States Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 140. Canada Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 141. Canada Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 142. Canada Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 143. Canada Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 144. Canada Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 145. Mexico Anticancer Drugs, by Application USD Million (2017-2022)
  • Table 146. Mexico Anticancer Drugs, by Drug Type USD Million (2017-2022)
  • Table 147. Mexico Anticancer Drugs, by Distribution Chanel USD Million (2017-2022)
  • Table 148. Mexico Anticancer Drugs, by Treatment Therapy USD Million (2017-2022)
  • Table 149. Mexico Anticancer Drugs, by Cancer Type USD Million (2017-2022)
  • Table 150. Anticancer Drugs Sales: by Application(K Tons)
  • Table 151. Anticancer Drugs Sales Hospitals & Clinics , by Region K Tons (2017-2022)
  • Table 152. Anticancer Drugs Sales Oncological Research Centres , by Region K Tons (2017-2022)
  • Table 153. Anticancer Drugs Sales: by Drug Type(K Tons)
  • Table 154. Anticancer Drugs Sales Targeted Drugs , by Region K Tons (2017-2022)
  • Table 155. Anticancer Drugs Sales Cytotoxic Drugs , by Region K Tons (2017-2022)
  • Table 156. Anticancer Drugs Sales: by Distribution Chanel(K Tons)
  • Table 157. Anticancer Drugs Sales Direct , by Region K Tons (2017-2022)
  • Table 158. Anticancer Drugs Sales Indirect , by Region K Tons (2017-2022)
  • Table 159. Anticancer Drugs Sales: by Treatment Therapy(K Tons)
  • Table 160. Anticancer Drugs Sales Chemotherapy , by Region K Tons (2017-2022)
  • Table 161. Anticancer Drugs Sales Radiation Therapy , by Region K Tons (2017-2022)
  • Table 162. Anticancer Drugs Sales Immunotherapy , by Region K Tons (2017-2022)
  • Table 163. Anticancer Drugs Sales Others , by Region K Tons (2017-2022)
  • Table 164. South America Anticancer Drugs Sales, by Country K Tons (2017-2022)
  • Table 165. South America Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 166. South America Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 167. South America Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 168. South America Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 169. South America Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 170. Brazil Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 171. Brazil Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 172. Brazil Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 173. Brazil Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 174. Brazil Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 175. Argentina Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 176. Argentina Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 177. Argentina Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 178. Argentina Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 179. Argentina Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 180. Rest of South America Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 181. Rest of South America Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 182. Rest of South America Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 183. Rest of South America Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 184. Rest of South America Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 185. Asia Pacific Anticancer Drugs Sales, by Country K Tons (2017-2022)
  • Table 186. Asia Pacific Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 187. Asia Pacific Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 188. Asia Pacific Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 189. Asia Pacific Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 190. Asia Pacific Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 191. China Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 192. China Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 193. China Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 194. China Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 195. China Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 196. Japan Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 197. Japan Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 198. Japan Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 199. Japan Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 200. Japan Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 201. India Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 202. India Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 203. India Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 204. India Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 205. India Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 206. South Korea Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 207. South Korea Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 208. South Korea Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 209. South Korea Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 210. South Korea Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 211. Taiwan Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 212. Taiwan Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 213. Taiwan Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 214. Taiwan Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 215. Taiwan Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 216. Australia Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 217. Australia Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 218. Australia Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 219. Australia Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 220. Australia Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 221. Rest of Asia-Pacific Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 222. Rest of Asia-Pacific Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 223. Rest of Asia-Pacific Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 224. Rest of Asia-Pacific Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 225. Rest of Asia-Pacific Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 226. Europe Anticancer Drugs Sales, by Country K Tons (2017-2022)
  • Table 227. Europe Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 228. Europe Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 229. Europe Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 230. Europe Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 231. Europe Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 232. Germany Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 233. Germany Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 234. Germany Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 235. Germany Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 236. Germany Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 237. France Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 238. France Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 239. France Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 240. France Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 241. France Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 242. Italy Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 243. Italy Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 244. Italy Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 245. Italy Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 246. Italy Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 247. United Kingdom Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 248. United Kingdom Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 249. United Kingdom Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 250. United Kingdom Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 251. United Kingdom Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 252. Netherlands Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 253. Netherlands Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 254. Netherlands Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 255. Netherlands Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 256. Netherlands Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 257. Rest of Europe Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 258. Rest of Europe Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 259. Rest of Europe Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 260. Rest of Europe Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 261. Rest of Europe Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 262. MEA Anticancer Drugs Sales, by Country K Tons (2017-2022)
  • Table 263. MEA Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 264. MEA Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 265. MEA Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 266. MEA Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 267. MEA Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 268. Middle East Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 269. Middle East Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 270. Middle East Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 271. Middle East Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 272. Middle East Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 273. Africa Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 274. Africa Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 275. Africa Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 276. Africa Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 277. Africa Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 278. North America Anticancer Drugs Sales, by Country K Tons (2017-2022)
  • Table 279. North America Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 280. North America Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 281. North America Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 282. North America Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 283. North America Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 284. United States Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 285. United States Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 286. United States Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 287. United States Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 288. United States Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 289. Canada Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 290. Canada Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 291. Canada Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 292. Canada Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 293. Canada Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 294. Mexico Anticancer Drugs Sales, by Application K Tons (2017-2022)
  • Table 295. Mexico Anticancer Drugs Sales, by Drug Type K Tons (2017-2022)
  • Table 296. Mexico Anticancer Drugs Sales, by Distribution Chanel K Tons (2017-2022)
  • Table 297. Mexico Anticancer Drugs Sales, by Treatment Therapy K Tons (2017-2022)
  • Table 298. Mexico Anticancer Drugs Sales, by Cancer Type K Tons (2017-2022)
  • Table 299. Company Basic Information, Sales Area and Its Competitors
  • Table 300. Company Basic Information, Sales Area and Its Competitors
  • Table 301. Company Basic Information, Sales Area and Its Competitors
  • Table 302. Company Basic Information, Sales Area and Its Competitors
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Anticancer Drugs: by Application(USD Million)
  • Table 313. Anticancer Drugs Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 314. Anticancer Drugs Oncological Research Centres , by Region USD Million (2023-2028)
  • Table 315. Anticancer Drugs: by Drug Type(USD Million)
  • Table 316. Anticancer Drugs Targeted Drugs , by Region USD Million (2023-2028)
  • Table 317. Anticancer Drugs Cytotoxic Drugs , by Region USD Million (2023-2028)
  • Table 318. Anticancer Drugs: by Distribution Chanel(USD Million)
  • Table 319. Anticancer Drugs Direct , by Region USD Million (2023-2028)
  • Table 320. Anticancer Drugs Indirect , by Region USD Million (2023-2028)
  • Table 321. Anticancer Drugs: by Treatment Therapy(USD Million)
  • Table 322. Anticancer Drugs Chemotherapy , by Region USD Million (2023-2028)
  • Table 323. Anticancer Drugs Radiation Therapy , by Region USD Million (2023-2028)
  • Table 324. Anticancer Drugs Immunotherapy , by Region USD Million (2023-2028)
  • Table 325. Anticancer Drugs Others , by Region USD Million (2023-2028)
  • Table 326. South America Anticancer Drugs, by Country USD Million (2023-2028)
  • Table 327. South America Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 328. South America Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 329. South America Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 330. South America Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 331. South America Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 332. Brazil Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 333. Brazil Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 334. Brazil Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 335. Brazil Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 336. Brazil Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 337. Argentina Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 338. Argentina Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 339. Argentina Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 340. Argentina Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 341. Argentina Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 342. Rest of South America Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 343. Rest of South America Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 344. Rest of South America Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 345. Rest of South America Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 346. Rest of South America Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 347. Asia Pacific Anticancer Drugs, by Country USD Million (2023-2028)
  • Table 348. Asia Pacific Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 349. Asia Pacific Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 350. Asia Pacific Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 351. Asia Pacific Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 352. Asia Pacific Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 353. China Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 354. China Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 355. China Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 356. China Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 357. China Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 358. Japan Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 359. Japan Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 360. Japan Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 361. Japan Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 362. Japan Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 363. India Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 364. India Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 365. India Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 366. India Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 367. India Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 368. South Korea Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 369. South Korea Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 370. South Korea Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 371. South Korea Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 372. South Korea Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 373. Taiwan Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 374. Taiwan Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 375. Taiwan Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 376. Taiwan Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 377. Taiwan Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 378. Australia Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 379. Australia Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 380. Australia Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 381. Australia Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 382. Australia Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 383. Rest of Asia-Pacific Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 384. Rest of Asia-Pacific Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 385. Rest of Asia-Pacific Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 386. Rest of Asia-Pacific Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 387. Rest of Asia-Pacific Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 388. Europe Anticancer Drugs, by Country USD Million (2023-2028)
  • Table 389. Europe Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 390. Europe Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 391. Europe Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 392. Europe Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 393. Europe Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 394. Germany Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 395. Germany Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 396. Germany Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 397. Germany Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 398. Germany Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 399. France Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 400. France Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 401. France Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 402. France Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 403. France Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 404. Italy Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 405. Italy Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 406. Italy Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 407. Italy Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 408. Italy Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 409. United Kingdom Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 410. United Kingdom Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 411. United Kingdom Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 412. United Kingdom Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 413. United Kingdom Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 414. Netherlands Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 415. Netherlands Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 416. Netherlands Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 417. Netherlands Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 418. Netherlands Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 419. Rest of Europe Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 420. Rest of Europe Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 421. Rest of Europe Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 422. Rest of Europe Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 423. Rest of Europe Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 424. MEA Anticancer Drugs, by Country USD Million (2023-2028)
  • Table 425. MEA Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 426. MEA Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 427. MEA Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 428. MEA Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 429. MEA Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 430. Middle East Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 431. Middle East Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 432. Middle East Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 433. Middle East Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 434. Middle East Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 435. Africa Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 436. Africa Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 437. Africa Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 438. Africa Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 439. Africa Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 440. North America Anticancer Drugs, by Country USD Million (2023-2028)
  • Table 441. North America Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 442. North America Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 443. North America Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 444. North America Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 445. North America Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 446. United States Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 447. United States Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 448. United States Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 449. United States Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 450. United States Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 451. Canada Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 452. Canada Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 453. Canada Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 454. Canada Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 455. Canada Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 456. Mexico Anticancer Drugs, by Application USD Million (2023-2028)
  • Table 457. Mexico Anticancer Drugs, by Drug Type USD Million (2023-2028)
  • Table 458. Mexico Anticancer Drugs, by Distribution Chanel USD Million (2023-2028)
  • Table 459. Mexico Anticancer Drugs, by Treatment Therapy USD Million (2023-2028)
  • Table 460. Mexico Anticancer Drugs, by Cancer Type USD Million (2023-2028)
  • Table 461. Anticancer Drugs Sales: by Application(K Tons)
  • Table 462. Anticancer Drugs Sales Hospitals & Clinics , by Region K Tons (2023-2028)
  • Table 463. Anticancer Drugs Sales Oncological Research Centres , by Region K Tons (2023-2028)
  • Table 464. Anticancer Drugs Sales: by Drug Type(K Tons)
  • Table 465. Anticancer Drugs Sales Targeted Drugs , by Region K Tons (2023-2028)
  • Table 466. Anticancer Drugs Sales Cytotoxic Drugs , by Region K Tons (2023-2028)
  • Table 467. Anticancer Drugs Sales: by Distribution Chanel(K Tons)
  • Table 468. Anticancer Drugs Sales Direct , by Region K Tons (2023-2028)
  • Table 469. Anticancer Drugs Sales Indirect , by Region K Tons (2023-2028)
  • Table 470. Anticancer Drugs Sales: by Treatment Therapy(K Tons)
  • Table 471. Anticancer Drugs Sales Chemotherapy , by Region K Tons (2023-2028)
  • Table 472. Anticancer Drugs Sales Radiation Therapy , by Region K Tons (2023-2028)
  • Table 473. Anticancer Drugs Sales Immunotherapy , by Region K Tons (2023-2028)
  • Table 474. Anticancer Drugs Sales Others , by Region K Tons (2023-2028)
  • Table 475. South America Anticancer Drugs Sales, by Country K Tons (2023-2028)
  • Table 476. South America Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 477. South America Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 478. South America Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 479. South America Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 480. South America Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 481. Brazil Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 482. Brazil Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 483. Brazil Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 484. Brazil Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 485. Brazil Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 486. Argentina Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 487. Argentina Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 488. Argentina Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 489. Argentina Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 490. Argentina Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 491. Rest of South America Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 492. Rest of South America Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 493. Rest of South America Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 494. Rest of South America Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 495. Rest of South America Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 496. Asia Pacific Anticancer Drugs Sales, by Country K Tons (2023-2028)
  • Table 497. Asia Pacific Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 498. Asia Pacific Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 499. Asia Pacific Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 500. Asia Pacific Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 501. Asia Pacific Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 502. China Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 503. China Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 504. China Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 505. China Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 506. China Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 507. Japan Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 508. Japan Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 509. Japan Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 510. Japan Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 511. Japan Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 512. India Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 513. India Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 514. India Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 515. India Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 516. India Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 517. South Korea Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 518. South Korea Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 519. South Korea Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 520. South Korea Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 521. South Korea Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 522. Taiwan Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 523. Taiwan Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 524. Taiwan Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 525. Taiwan Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 526. Taiwan Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 527. Australia Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 528. Australia Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 529. Australia Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 530. Australia Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 531. Australia Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 532. Rest of Asia-Pacific Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 533. Rest of Asia-Pacific Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 534. Rest of Asia-Pacific Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 535. Rest of Asia-Pacific Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 536. Rest of Asia-Pacific Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 537. Europe Anticancer Drugs Sales, by Country K Tons (2023-2028)
  • Table 538. Europe Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 539. Europe Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 540. Europe Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 541. Europe Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 542. Europe Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 543. Germany Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 544. Germany Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 545. Germany Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 546. Germany Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 547. Germany Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 548. France Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 549. France Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 550. France Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 551. France Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 552. France Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 553. Italy Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 554. Italy Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 555. Italy Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 556. Italy Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 557. Italy Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 558. United Kingdom Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 559. United Kingdom Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 560. United Kingdom Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 561. United Kingdom Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 562. United Kingdom Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 563. Netherlands Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 564. Netherlands Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 565. Netherlands Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 566. Netherlands Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 567. Netherlands Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 568. Rest of Europe Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 569. Rest of Europe Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 570. Rest of Europe Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 571. Rest of Europe Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 572. Rest of Europe Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 573. MEA Anticancer Drugs Sales, by Country K Tons (2023-2028)
  • Table 574. MEA Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 575. MEA Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 576. MEA Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 577. MEA Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 578. MEA Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 579. Middle East Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 580. Middle East Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 581. Middle East Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 582. Middle East Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 583. Middle East Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 584. Africa Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 585. Africa Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 586. Africa Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 587. Africa Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 588. Africa Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 589. North America Anticancer Drugs Sales, by Country K Tons (2023-2028)
  • Table 590. North America Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 591. North America Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 592. North America Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 593. North America Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 594. North America Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 595. United States Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 596. United States Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 597. United States Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 598. United States Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 599. United States Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 600. Canada Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 601. Canada Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 602. Canada Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 603. Canada Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 604. Canada Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 605. Mexico Anticancer Drugs Sales, by Application K Tons (2023-2028)
  • Table 606. Mexico Anticancer Drugs Sales, by Drug Type K Tons (2023-2028)
  • Table 607. Mexico Anticancer Drugs Sales, by Distribution Chanel K Tons (2023-2028)
  • Table 608. Mexico Anticancer Drugs Sales, by Treatment Therapy K Tons (2023-2028)
  • Table 609. Mexico Anticancer Drugs Sales, by Cancer Type K Tons (2023-2028)
  • Table 610. Research Programs/Design for This Report
  • Table 611. Key Data Information from Secondary Sources
  • Table 612. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anticancer Drugs: by Application USD Million (2017-2022)
  • Figure 5. Global Anticancer Drugs: by Drug Type USD Million (2017-2022)
  • Figure 6. Global Anticancer Drugs: by Distribution Chanel USD Million (2017-2022)
  • Figure 7. Global Anticancer Drugs: by Treatment Therapy USD Million (2017-2022)
  • Figure 8. South America Anticancer Drugs Share (%), by Country
  • Figure 9. Asia Pacific Anticancer Drugs Share (%), by Country
  • Figure 10. Europe Anticancer Drugs Share (%), by Country
  • Figure 11. MEA Anticancer Drugs Share (%), by Country
  • Figure 12. North America Anticancer Drugs Share (%), by Country
  • Figure 13. Global Anticancer Drugs: by Application K Tons (2017-2022)
  • Figure 14. Global Anticancer Drugs: by Drug Type K Tons (2017-2022)
  • Figure 15. Global Anticancer Drugs: by Distribution Chanel K Tons (2017-2022)
  • Figure 16. Global Anticancer Drugs: by Treatment Therapy K Tons (2017-2022)
  • Figure 17. South America Anticancer Drugs Share (%), by Country
  • Figure 18. Asia Pacific Anticancer Drugs Share (%), by Country
  • Figure 19. Europe Anticancer Drugs Share (%), by Country
  • Figure 20. MEA Anticancer Drugs Share (%), by Country
  • Figure 21. North America Anticancer Drugs Share (%), by Country
  • Figure 22. Global Anticancer Drugs share by Players 2022 (%)
  • Figure 23. Global Anticancer Drugs share by Players (Top 3) 2022(%)
  • Figure 24. Global Anticancer Drugs share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 28. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 30. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 31. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Hoffmann-La Roche Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Hoffmann-La Roche Ltd. (United States) Revenue: by Geography 2022
  • Figure 38. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. Astra Zeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 40. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 42. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 43. Celgene (United States) Revenue: by Geography 2022
  • Figure 44. Eli Lilly & Co (United States) Revenue, Net Income and Gross profit
  • Figure 45. Eli Lilly & Co (United States) Revenue: by Geography 2022
  • Figure 46. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 47. Cadila Healthcare Limited (India) Revenue: by Geography 2022
  • Figure 48. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 49. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2022
  • Figure 50. LOGENEX Pharm GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 51. LOGENEX Pharm GmbH (Germany) Revenue: by Geography 2022
  • Figure 52. Global Anticancer Drugs: by Application USD Million (2023-2028)
  • Figure 53. Global Anticancer Drugs: by Drug Type USD Million (2023-2028)
  • Figure 54. Global Anticancer Drugs: by Distribution Chanel USD Million (2023-2028)
  • Figure 55. Global Anticancer Drugs: by Treatment Therapy USD Million (2023-2028)
  • Figure 56. South America Anticancer Drugs Share (%), by Country
  • Figure 57. Asia Pacific Anticancer Drugs Share (%), by Country
  • Figure 58. Europe Anticancer Drugs Share (%), by Country
  • Figure 59. MEA Anticancer Drugs Share (%), by Country
  • Figure 60. North America Anticancer Drugs Share (%), by Country
  • Figure 61. Global Anticancer Drugs: by Application K Tons (2023-2028)
  • Figure 62. Global Anticancer Drugs: by Drug Type K Tons (2023-2028)
  • Figure 63. Global Anticancer Drugs: by Distribution Chanel K Tons (2023-2028)
  • Figure 64. Global Anticancer Drugs: by Treatment Therapy K Tons (2023-2028)
  • Figure 65. South America Anticancer Drugs Share (%), by Country
  • Figure 66. Asia Pacific Anticancer Drugs Share (%), by Country
  • Figure 67. Europe Anticancer Drugs Share (%), by Country
  • Figure 68. MEA Anticancer Drugs Share (%), by Country
  • Figure 69. North America Anticancer Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • Pfizer Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Hoffmann-La Roche Ltd. (United States)
  • Astra Zeneca (United Kingdom)
  • AbbVie Inc. (United States)
  • Celgene (United States)
  • Eli Lilly & Co (United States)
  • Cadila Healthcare Limited (India)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • LOGENEX Pharm GmbH (Germany)
Additional players considered in the study are as follows:
Shilpa Therapeutics Pvt. Ltd (India) , Amgen (United States) , AQVIDA GmbH (Germany) ,
Select User Access Type

Key Highlights of Report


May 2023 222 Pages 93 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anticancer Drugs research Quantitative research analysis
Global Anticancer Drugs research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Anticancer Drugs Market are by end use application [Hospitals & Clinics and Oncological Research Centres].
The Anticancer Drugs Market is gaining popularity and expected to see strong valuation by 2028.
  • Growing Expenditure of Pharmaceutical Industry
  • Increasing Cancer Incidence across the Globe
  • Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments

Know More About Global Anticancer Drugs research Report?

Have a Query? Click Here

Other Related Reports

CBD Hemp Oil Comprehensive Study by Type (Inorganic Source, Organic Source), Application (Pharmaceuticals Industry, Food Industry, Cosmetic Industry, Others) Players and Region - Global Market Outloo...
$ 3500
Male Hypogonadism Comprehensive Study by Type (Primary hypogonadism(Genetic, congenital), Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)), Application (Kallmann Syndrome, Klinefelte...
$ 3750
Insomnia Drugs Comprehensive Study by Type (Prescription-based Drugs, OTC Drugs, Herbal Drugs), Application (Hospitals, Clinics, Research Centres, Others), Distribution Channel (Retail Pharmacies, On...
$ 3450
Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory ...
$ 3450
Heavy Metal Poisoning Drugs Comprehensive Study by Type (ALN-TMP, Deferasirox, Deferoxamine Mesylate, Emeramide, Others), Application (Arsenic Toxicity, Chromium Toxicity, Copper Toxicity, Lead Toxic...
$ 3750
Pharmaceutical Robots Comprehensive Study by Type (Traditional Robots {Articulated, SCARA, Delta Parallel and Cartesian}, Collaborative Robots), Application (Picking and Packaging, Inspection of Drug...
$ 3450